Evidence map›Paper›PMID 39969781›Full record

ArticleAdvances in therapy2025

Real-world Outcomes Following Biologic Initiation in US Patients with Chronic Rhinosinusitis with Nasal Polyps.

Anju Peters, Xiaohui Zhao, Aimee M Near, Joseph Han, Joseph D Spahn, Sze-Jung S Wu, Andrew W Lindsley, Tham T Le, Elizabeth J Wang, Rifat Tuly and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anju PetersDivision of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Xiaohui ZhaoIQVIA, Durham, NC, USA.
Aimee M NearIQVIA, Durham, NC, USA.
Joseph HanDepartment of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
Joseph D SpahnRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Sze-Jung S WuRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Andrew W LindsleyUS Medical Affairs, Amgen, Thousand Oaks, CA, USA.
Tham T LeRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Elizabeth J WangIQVIA, Durham, NC, USA.
Rifat TulyIQVIA, Durham, NC, USA.
Inyoung LeeIQVIA, Durham, NC, USA.
Christopher S AmbroseRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA. chris.ambrose@astrazeneca.com.ORCID 0000-0003-4175-7336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic rhinosinusitis with nasal polyposis (CRSwNP) is often associated with persistent symptoms and impaired quality of life despite treatment with intranasal corticosteroids. Biologics (dupilumab, mepolizumab, omalizumab) have been recently approved for CRSwNP. This study aims to characterize biologic use and real-world outcomes, including medication use and nasal polyps (NP) surgeries, following biologic treatment in US patients with CRSwNP.

methodsThis retrospective cohort study analyzed linked data from IQVIA longitudinal prescription and medical claims databases (July 2018-June 2023). Patients evaluated included those with ≥ 2 diagnoses of CRSwNP and ≥ 12 months of baseline data (overall cohort, index = first observed CRSwNP diagnosis) as well as patients with CRSwNP who received ≥ 2 consecutive biologic doses and had ≥ 24 months of follow-up data (biologic cohort, index = first biologic).

resultsOf 74,480 patients with CRSwNP, 8716 (12.0%) received a biologic and 2208 met all inclusion criteria. Dupilumab was the most frequently received biologic (89.8%; mepolizumab, 5.3%; omalizumab, 4.8%). Relative to the overall cohort, the biologic cohort was younger (mean age: 52.6 vs. 57.6 years), had more women (54.0% vs. 46.1%) and had a higher baseline prevalence of asthma (72.4% vs. 30.9%), allergic rhinitis (70.6% vs. 37.4%), NP surgery (15.8% vs. 5.8%), oral corticosteroid (OCS) use (84.0% vs. 51.8%), and antibiotic use (84.2% vs. 68.7%). During the 24 months after biologic initiation, 65.6% of patients had ≥ 1 OCS use (≥ 2 OCS uses during months 1-12, 27.0%; during months 13-24, 27.0%) and 77.9% had ≥ 1 antibiotic use; and 7.1% of patients without NP surgery before biologic initiation had ≥ 1 NP surgery during follow-up. Almost half of patients (49.3%) discontinued (≥ 90 days without receipt) their initial biologic during follow-up.

conclusionBiologic use was relatively low among US patients with CRSwNP. OCS and antibiotic usage among patients with CRSwNP remained substantial despite use of currently approved biologics, indicating an unmet need for improved treatment options.

Indexed as

Biological ProductsNasal PolypsRhinitisSinusitisAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseFemaleHumansMaleMiddle AgedOmalizumabRetrospective StudiesRhinosinusitisTreatment OutcomeAntibodies, Monoclonal, HumanizedBiological ProductsdupilumabmepolizumabOmalizumabAllergist/immunologistBiologicsChronic rhinosinusitis with nasal polyposis (CRSwNP)DupilumabEar-nose-throatMepolizumabOmalizumabOtolaryngologistReal-world data

Identifiers

PMID39969781
PMCPMC11929629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.